netFormulary North of Tyne, Gateshead and North Cumbria NHS
Area Prescribing Committee Formulary  
 Search
 Formulary Chapter 5: Infections - Full Chapter
05.03.01  Expand sub section  HIV infection
05.03.01  Expand sub section  Nucleoside reverse transcriptase inhibitors
Abacavir
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Didanosine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Emtricitabine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Lamivudine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • 150 mg and 300 mg tablets
  • 50 mg/5ml oral solution
 
   
Stavudine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Tenofovir Disoproxil
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Zidovudine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
05.03.01  Expand sub section  Protease inhibitors
Saquinavir
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Tipranavir
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Atazanavir
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • For limited use as part of triple therapy where other protease inhibitors are unsuitable
 
   
Atazanavir sulfate and cobicistat
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

To be used in accordance with NHS England Clinical Commissioning Policy (SSC1614).

 
   
Darunavir
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Darunavir and Cobicistat
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

To be used in accordance with NHS England Clinical Commissioning Policy (SSC1614).

 
   
Fosamprenavir
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Indinavir
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Nelfinavir
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Ritonavir
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
05.03.01  Expand sub section  Non-nucleoside reverse transcriptase inhibitors
Efavirenz (Sustiva®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Etravirine (Intelence®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Nevirapine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Rilpivirine hydrochloride
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • For patients who, due to renal impairment, require reduced doses that are not able to be accommodated by the fixed combination product.
 
   
05.03.01  Expand sub section  Other antiretrovirals to top
Dolutegravir
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Enfuvirtide
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Maraviroc
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • Approved for use in the treatment of patients with HIV infections that are resistant to standard therapy in accordance with British HIV Association and EACS guidelines.
 
   
Raltegravir
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • Approved for use in the treatment of patients with HIV infections that are resistant to standard therapy in accordance with British HIV Association and EACS guidelines.
 
   
05.03.01  Expand sub section  Pharmacokinetic enhancers of anti-retrovirals
Cobicistat (Tybost®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  Clinical Commissioning Policy F03/P/b: Use of cobicistat as a booster in treatment of HIV positive adults and adolescents
   
05.03.01  Expand sub section  Combination Products
Abacavir & Lamivudine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Abacavir & Lamivudine & Zidovudine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Abacavir & Lamivudine & Dolutegravir
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Tenofovir Disoproxil & Emtricitabine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Lopinavir and Ritonavir (Kaletra®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Tenofovir Disoproxil & Emtricitabine & Rilpivirine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Tenofovir Disproxil & Cobicistat & Elvitegravir & Emtricitabine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • To be used in accordance with NHS England Clinical Commissioning Policy.
 
   
Tenofovir Disproxil & Efavirenz & Emtricitabine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
Tenofovir alafenamide & Cobicistat & Emtricitabine & Elvitegravir  (Genvoya®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • To be used in accordance with NHS England Clinical Commissioning Policy.
 
   
Tenofovir alafenamide & Emtricitabine
(Descovy®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Film coated tablets containing:
    • emtricitabine 200mg & tenofovir alafenamide (as fumarate) 10mg
    • emtricitabine 200mg & tenofovir alafenamide (as fumarate) 25mg

  • To be used in accordance with NHS England Clinical Commissioning Policy.
 
   
Tenofovir alafenamide & Emtricitabine & Rilpivirine  (Odefsey®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Film coated tablets containing rilpivirine 25mg, emtricitabine 200mg & tenofovir alafenamide (as fumarate) 25mg
  • To be used in accordance with NHS England Clinical Commissioning Policy.
 
   
Zidovudine & Lamivudine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Drugs for hospital use only. The responsibility for initiation and monitoring treatment should rest with an appropriate hospital clinician and the drug should be supplied through the hospital throughout the duration of treatment. In some very exceptional circumstances (e.g. due to distance from the hospital, storage, supply or mobility/transport problems) it may be appropriate for the GP to be asked to prescribe a Red drug. This should be negotiated on an individual patient basis and should only be done with the GP’s prior informed agreement where the roles of the GP and hospital services are clearly defined and agreed. The GP should not feel under pressure to prescribe in these circumstances.   

Amber

Drugs initiated by hospital specialist, but where continuing treatment by GPs may be appropriate under a shared care arrangement. The specialist should send the GP a copy of the shared care agreement to sign. The GP should sign the shared care agreement, or indicate they do not want to be part of such an agreement, and return a copy back to the specialist. Shared care guidelines are available or are being developed for most of the drugs listed as Amber. If no shared care guideline is available, the hospital specialist should provide the patient’s GP with sufficient information and support to allow treatment to be continued and managed safely in primary care.  

Green plus

Drugs normally recommended or initiated by hospital specialist, but where the provision of an information leaflet may be appropriate to facilitate continuing treatment by GPs. Many of these information sheets are in the process of development.  

Green

Drugs where prescribing by GPs is appropriate. Drugs not classified as Red, Amber or Green Plus (formerly blue in North of Tyne) are generally classified as ‘Green’ by default. The Green drugs listed here include those products normally initiated by hospital specialists where there was a need for discussion and debate as to the category in which they should be placed.  

netFormulary